- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
The stock has been on fire.
If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.
Plus more from the biotechnology world on Wednesday, June 7.
The magnetic tape cartridges in the company's products will be under review.